| Date | Title | Description | Source |
| 06.03.2024 | HOOKIPA Pharma to Participate in Leerink Partners Global Bio... | - | globenewsw... |
| 21.12.2023 | HOOKIPA Pharma Announces $21.25 Million Equity Investment fr... | - | globenewsw... |
| 10.06.2023 | HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Li... | /EIN News/ -- NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (N... | einpresswi... |
| 14.04.2023 | HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Li... | /EIN News/ -- NEW YORK and VIENNA, Austria, April 14, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (... | einpresswi... |
| 04.04.2023 | Startup Showcase: Hookipa Pharma – Developing Revolutionary ... | Hookipa Pharma is a clinical stage biotech company located in Vienna, Austria, that is developing ne... | eustartup.... |
| 20.10.2022 | HOOKIPA announces strategic collaboration and license agreem... | Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed nov... | globenewsw... |
| 07.09.2022 | HOOKIPA Pharma to Participate in Upcoming Investor Conferenc... | NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’... | globenewsw... |
| 11.08.2022 | HOOKIPA Pharma Reports Second Quarter 2022 Financial Results... | HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and neck cancer ... | globenewsw... |
| 25.07.2022 | FDA accepts HOOKIPA’s Investigational New Drug Application f... | Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/... | globenewsw... |
| 21.06.2022 | HOOKIPA Announces Executive Leadership Changes | NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘... | globenewsw... |
| 05.06.2022 | HOOKIPA announces positive Phase 1 data and Phase 2 plans fo... | Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tum... | globenewsw... |
| 03.06.2022 | Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccine... | Oral and poster presentations highlight robust and high-quality immune responses following administr... | globenewsw... |
| 26.05.2022 | HOOKIPA to Present Complete HB-200 Phase 1 Results and Recom... | Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rap... | globenewsw... |
| 16.05.2022 | HOOKIPA Pharma Reports First Quarter 2022 Financial Results ... | HB-200 program on track to report Phase 1 data mid-year, Phase 2 data in combination with pembrolizu... | globenewsw... |
| 09.05.2022 | HOOKIPA Pharma to Report First Quarter 2022 Financial Result... | NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘H... | globenewsw... |
| 03.05.2022 | HOOKIPA Pharma to Participate in Upcoming Investor Conferenc... | NEW YORK and VIENNA, Austria, May 03, 2022 (GLOBE NEWSWIRE) -- New York, US and Vienna, Austria, May... | globenewsw... |
| 13.04.2022 | HOOKIPA to Participate in the Kempen Life Sciences Conferenc... | NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ... | globenewsw... |
| 24.03.2022 | HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial ... | Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging a... | globenewsw... |
| 17.03.2022 | HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 F... | NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ... | globenewsw... |
| 02.03.2022 | HOOKIPA Pharma Announces Pricing of $75.0 Million Public Off... | NEW YORK and VIENNA, Austria, March 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK),... | globenewsw... |
| 15.02.2022 | HOOKIPA and Gilead Amend Collaboration and License Agreement... | HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; ... | globenewsw... |
| 09.02.2022 | HOOKIPA to Present at the SVB Leerink Global Healthcare Conf... | NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘... | globenewsw... |
| 19.01.2022 | HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Ev... | NEW YORK and VIENNA, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a... | marketscre... |
| 18.01.2022 | HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Ev... | First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/met... | globenewsw... |
| 18.01.2022 | HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Ev... | First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/met... | marketscre... |
| 04.01.2022 | HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect ... | NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘... | globenewsw... |
| 12.11.2021 | HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtua... | NEW YORK and VIENNA, Austria, Nov. 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘... | globenewsw... |
| 10.11.2021 | HOOKIPA Pharma Reports Third Quarter 2021 Financial Results ... | Clinical collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, set to evaluate HB-201 in co... | globenewsw... |
| 09.11.2021 | HOOKIPA advances HB-200 program to Phase 2 and prioritizes o... | Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combinat... | globenewsw... |
| 03.11.2021 | HOOKIPA Pharma to Report Third Quarter 2021 Financial Result... | NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘... | globenewsw... |
| 14.10.2021 | HOOKIPA announces publication on the benefits of its novel a... | Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immuno... | globenewsw... |
| 14.10.2021 | HOOKIPA Pharma : announces publication on the benefits of it... | Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immuno... | marketscre... |
| 16.09.2021 | HOOKIPA Pharma : announces clinical collaboration with Merck... | NEW YORK and VIENNA, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a... | marketscre... |
| 15.09.2021 | HOOKIPA Pharma : announces clinical collaboration with Merck... | Clinical collaboration to assess HB-200 in combination with KEYTRUDA® (pembrolizumab) as first-line ... | marketscre... |
| 12.04.2021 | HOOKIPA PHARMA INC.
HOOKIPA Pharma : announces positive pre... | NEW YORK and VIENNA, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a... | marketscre... |
| 10.04.2021 | AACR roundup: Arcus rolls out PhI data on adenosine block... | Arcus Biosciences’ adenosine blocker etrumadenant showed some benefit in extending patient... | endpts.com... |
| 10.04.2021 | HOOKIPA PHARMA INC.
HOOKIPA announces positive preliminary ... | Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of cir... | marketscre... |
| 18.03.2021 | HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial ... | Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with int... | globenewsw... |
| 09.03.2021 | HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 F... | NEW YORK and VIENNA, Austria, March 09, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ... | globenewsw... |
| 04.03.2021 | Pre-clinical data on HOOKIPA’s alternating 2-vector cancer t... | Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific ... | globenewsw... |
| 03.03.2021 | HOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Gl... | NEW YORK and VIENNA, Austria, March 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ... | globenewsw... |
| 16.02.2021 | HOOKIPA Pharma to Participate in Upcoming SVB Leerink Global... | NEW YORK and VIENNA, Austria, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘... | globenewsw... |
| 18.04.2019 | Gilead-partnered Vienna-based immunotherapy company ... | Gilead-partnered immunotherapy developer Hookipa has been working on technology using ar... | endpts.com... |
| 26.02.2019 | HOOKIPA Pharma Raises $37.4M in Series D Financing | NEW YORK & VIENNA--(BUSINESS WIRE)--HOOKIPA Pharma Inc., a company developing a new class of imm... | citybizlis... |
| 26.02.2019 | Hookipa Pharma Raises $37.4M in Series D Financing | Hookipa Pharma Inc., a NYC- and Vienna, Austria-based company developing a new class of immunotherap... | finsmes.co... |
| 26.02.2019 | HOOKIPA Pharma Raises $37.4M in Series D Financing | NEW YORK & VIENNA--(BUSINESS WIRE)--HOOKIPA Pharma Inc., a company developing a new class of imm... | archive.ci... |
| 11.12.2017 | Hookipa Biotech Raises $60 million (€50 million) in an Overs... | Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of i... | forbion.co... |
| 04.11.2013 | Hookipa Biotech Closes €20 Million($27.5 Million) in Series ... | Hookipa Biotech AG, a company pioneering a new class of vaccines, today announced that it has raised... | forbion.co... |
| 04.11.2013 | Hookipa Biotech Raises €20M in Series B Equity Financing | Hookipa Biotech AG, a Vienna, Austria-based developer of a new class of vaccines, raised €20m ($27.5... | finsmes.co... |
| 26.10.2011 | Hookipa Biotech Raises €7M in Series A Financing | Hookipa Biotech, an Austrian biotech startup specialized in developing new generation vaccines, has ... | finsmes.co... |
